These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28133766)

  • 1. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.
    Ivaturi V; Gopalakrishnan M; Gobburu JVS; Zhang W; Liu Y; Heidbreder C; Laffont CM
    Br J Clin Pharmacol; 2017 Jul; 83(7):1476-1498. PubMed ID: 28133766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
    Nasser AF; Henderson DC; Fava M; Fudala PJ; Twumasi-Ankrah P; Kouassi A; Heidbreder C
    J Clin Psychopharmacol; 2016 Apr; 36(2):130-40. PubMed ID: 26862829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone plasma levels, clinical response and side-effects.
    Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
    Turkoz I; Bossie CA; Lindenmayer JP; Schooler N; Canuso CM
    BMC Psychiatry; 2011 Feb; 11():21. PubMed ID: 21299844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
    Gomeni R; Heidbreder C; Fudala PJ; Nasser AF
    J Clin Pharmacol; 2013 Oct; 53(10):1010-9. PubMed ID: 23868656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
    Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.
    Takekita Y; Koshikawa Y; Fabbri C; Sakai S; Sunada N; Onohara A; Nishida K; Yoshimura M; Kato M; Serretti A; Kinoshita T
    BMC Psychiatry; 2016 May; 16():172. PubMed ID: 27236412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study.
    Filts Y; Litman RE; Martínez J; Anta L; Naber D; Correll CU
    Schizophr Res; 2022 Jan; 239():83-91. PubMed ID: 34847501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.
    Schreiner A; Bergmans P; Cherubin P; Keim S; Llorca PM; Cosar B; Petralia A; Corrivetti G; Hargarter L
    J Psychopharmacol; 2015 Aug; 29(8):910-22. PubMed ID: 25999398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program.
    Andorn A; Graham J; Csernansky J; Newcomer JW; Shinde S; Muma G; Heidbreder C; Fava M
    J Clin Psychopharmacol; 2019; 39(5):428-433. PubMed ID: 31343440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
    Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
    Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.
    Isitt JJ; Nadipelli VR; Kouassi A; Fava M; Heidbreder C
    Schizophr Res; 2016 Jul; 174(1-3):126-131. PubMed ID: 27066860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly Extended-Release Risperidone) in Schizophrenia Patients.
    Le Moigne A; Csernansky J; Leadbetter RA; Andorn AC; Graham JA; Heath AT; Walling DP; Newcomer JW; Marder SR
    J Clin Psychiatry; 2021 Sep; 82(5):. PubMed ID: 34551218
    [No Abstract]   [Full Text] [Related]  

  • 16. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia.
    Meltzer HY; Lindenmayer JP; Kwentus J; Share DB; Johnson R; Jayathilake K
    Schizophr Res; 2014 Apr; 154(1-3):14-22. PubMed ID: 24630262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
    Sliwa JK; Bossie CA; Ma YW; Alphs L
    Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
    Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K
    Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia.
    Lauriello J; McEvoy JP; Rodriguez S; Bossie CA; Lasser RA
    Schizophr Res; 2005 Jan; 72(2-3):249-58. PubMed ID: 15560969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.